Gavreto - direct healthcare professional communication (DHPC)

pralsetinib

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Gavreto (pralsetinib): Increased risk for tuberculosis and measures to minimise this risk

Key facts

• Medicine name:
  Gavreto
• Active substance:
  pralsetinib
• Therapeutic area (MeSH):
  Carcinoma, Non-Small-Cell Lung
• Procedure number:
  EMEA/H/C/005413
• Regulatory outcome:
  Variation
• DHPC type:
  • Adverse event
  • Post-authorisation measure
• Human ATC codes:
  L01XE
• Dissemination date:
  16/06/2023